BR0315596A - Tetralinas e indanos substituìdos - Google Patents

Tetralinas e indanos substituìdos

Info

Publication number
BR0315596A
BR0315596A BR0315596-0A BR0315596A BR0315596A BR 0315596 A BR0315596 A BR 0315596A BR 0315596 A BR0315596 A BR 0315596A BR 0315596 A BR0315596 A BR 0315596A
Authority
BR
Brazil
Prior art keywords
indans
substituted tetralines
tetralines
substituted
tetralins
Prior art date
Application number
BR0315596-0A
Other languages
English (en)
Inventor
Xiaoli Chen
Keith T Demarest
Jung Lee
Jay M Matthews
Philip Rybczynski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0315596A publication Critical patent/BR0315596A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TETRALINAS E INDANOS SUBSTITUìDOS". A invenção refere-se a compostos de tetralina e indano, composições contendo-os e métodos de uso dos mesmos como moduladores de PPAR alfa para tratar ou inibir a progressão de, por exemplo, dislipidemia.
BR0315596-0A 2002-10-21 2003-10-17 Tetralinas e indanos substituìdos BR0315596A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41993502P 2002-10-21 2002-10-21
US49527003P 2003-08-15 2003-08-15
PCT/US2003/033090 WO2004037778A1 (en) 2002-10-21 2003-10-17 Substituted tetralins and indanes

Publications (1)

Publication Number Publication Date
BR0315596A true BR0315596A (pt) 2005-09-06

Family

ID=32179771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315596-0A BR0315596A (pt) 2002-10-21 2003-10-17 Tetralinas e indanos substituìdos

Country Status (17)

Country Link
EP (1) EP1569897A1 (pt)
JP (1) JP2006503916A (pt)
KR (1) KR20050055773A (pt)
AU (1) AU2003277441B2 (pt)
BR (1) BR0315596A (pt)
CA (1) CA2502661A1 (pt)
CR (1) CR7795A (pt)
EA (1) EA009553B1 (pt)
EG (1) EG24842A (pt)
HR (1) HRP20050335A2 (pt)
MX (1) MXPA05004191A (pt)
NO (1) NO20052199L (pt)
NZ (1) NZ539510A (pt)
PL (1) PL376325A1 (pt)
RS (1) RS20050318A (pt)
TW (1) TW200418773A (pt)
WO (1) WO2004037778A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004192A (es) * 2002-10-21 2005-09-20 Johnson & Johnson Tetralinas e indanos sustituidos.
KR20050067419A (ko) * 2002-10-21 2005-07-01 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단으로의 ｘ 증후군의 치료
AR048931A1 (es) * 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
EP1804785A2 (en) * 2004-10-27 2007-07-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
EP1259494A4 (en) * 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES
HUP0302306A3 (en) * 2000-10-05 2005-02-28 Bayer Ag Propionic acid derivatives with ppar-alpha activating properties
JPWO2002044129A1 (ja) * 2000-11-29 2004-04-02 杏林製薬株式会社 置換カルボン酸誘導体
AU2002222573A1 (en) * 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
JP2004520397A (ja) * 2001-02-15 2004-07-08 ファイザー・プロダクツ・インク 増殖性アクチベータ受容体（ｐｐａｒ）化合物
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
MXPA05004192A (es) * 2002-10-21 2005-09-20 Johnson & Johnson Tetralinas e indanos sustituidos.
KR20050067419A (ko) * 2002-10-21 2005-07-01 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단으로의 ｘ 증후군의 치료

Also Published As

Publication number Publication date
TW200418773A (en) 2004-10-01
AU2003277441A1 (en) 2004-05-13
EG24842A (en) 2010-10-13
JP2006503916A (ja) 2006-02-02
AU2003277441B2 (en) 2009-05-07
RS20050318A (en) 2007-09-21
CA2502661A1 (en) 2004-05-06
CR7795A (es) 2012-10-25
PL376325A1 (en) 2005-12-27
NZ539510A (en) 2008-01-31
NO20052199L (no) 2005-06-24
EA200500515A1 (ru) 2005-10-27
EA009553B1 (ru) 2008-02-28
KR20050055773A (ko) 2005-06-13
HRP20050335A2 (en) 2006-05-31
MXPA05004191A (es) 2006-01-27
EP1569897A1 (en) 2005-09-07
WO2004037778A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
PT1237553E (pt) Combinacao de um inibidor de recaptacao da serotonina e de um antagonista, de um agonista inverso ou de um agonista parcial para o 5-ht2c
UY24949A1 (es) Compuestos calcilíticos
BR0315566A (pt) Tetralinas e indanos substituìdos
BR9900320A (pt) Composição antimicrobiana
ECSP066434A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
CR7868A (es) Combinacion para el tratamiento del trastorno por deficit de atencion con hiperactividad
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
UY26130A1 (es) Compuestos para tratar la obesidad
ES2165441T3 (es) Inhibidores de calpaina y/o catepsina b oxazolidin sustituidos.
IL168147A (en) Substituted tetralins and indanes and their use
NI202100018A (es) Moduladores de la expresión de pnpla3
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ECSP077319A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos, y analogos de los mismos
ECSP066435A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
ECSP077320A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
AR016981A2 (es) Polipeptidos sinteticos
BR0315596A (pt) Tetralinas e indanos substituìdos
CR20130055A (es) Compuestos aromáticos apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
BR0213581A (pt) Uso de um inibidor de recaptação de norepinefrina seletivo
ECSP003590A (es) Compuestos calcioliticos
ECSP003458A (es) Compuestos para tratar la obesidad

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Application fees: publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.